A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors

The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).

Study Overview

• Status: Recruiting
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: BB-1705

Detailed Description

Phase Ia is a dose escalation study to assess the safety and tolerability, and to determine the MTD or MAD and RP2D of BB-1705.

Phase Ib is a cohort expansion study to explore one or more RP2Ds to further assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Patients with locally advanced and unresectable or metastatic solid tumors who have progressed on prior lines of standard of care therapies will be enrolled in this study if eligible.

• Study Type: Interventional
• Enrollment (Estimated): 288
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Recruiting
    • Beijing Cancer Hospital
    • Contact: SHEN LIN; Phone Number: 13911219511; Email: doctorshenlin@sina.cn
  • Changsha, China
    • Recruiting
    • Hunan Cancer Hospital
    • Contact: LIN JINGUAN; Phone Number: 13307318568; Email: linjingguan@hnca.org.cn
  • Ganzhou, China
    • Recruiting
    • First Affiliated hospital of GANNAN Medical University
    • Contact: SHI HUAQIU; Phone Number: 13576666365; Email: shq3677274@163.com
  • Hangzhou, China
    • Recruiting
    • Bliss Biopharmaceutical Co, Ltd
    • Contact: Tang Huoling; Phone Number: 17301835287; Email: yyang@blissbiopharma.com
  • Hanzhou, China
    • Recruiting
    • Zhejiang University School of Medicine - The First Affiliated Hospital
    • Contact: ZHENG YULONG; Phone Number: 13588166206; Email: zn_loogen@126.com
  • Linyi, China
    • Recruiting
    • Linyi Cancer Hospital
    • Contact: SHI JIANGHUA; Phone Number: 15963998868; Email: shijianhualy@126.com
  • Nanjing, China
    • Recruiting
    • Jiangsu Province Hospital
    • Contact: GUAN XIANGXIAN; Phone Number: 13512510329; Email: xguan@njmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Willing and able to provide written informed consent form (ICF) for the trial.
2. Adult patients ≥ 18 years at the time of signing ICF.
3. Patient must have a histologically or cytologically confirmed, locally advanced, unresectable, or metastatic solid tumors:
4. At least one measurable lesion as defined per RECIST Version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy ≥12 weeks.
7. Adequate organ function as indicated by the following laboratory values (had not received blood transfusion, EPO, G-CSF, or other medical support within the 14 days before the administration of BB-1705):
8. Women of childbearing potential and males with fertile female partner must be willing to use currently accepted reliable contraception method throughout the treatment period from ICF signed and for at least 6 months following the last dose of BB-1705. These measures include, but are not limited to, oral or implantable injections of hormonal contraceptives; intrauterine birth control ring or placement of IUS intrauterine device); or use of barrier methods such as condoms or septum and spermicide products. Postmenopausal women over 50 years of age must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative pregnancy test ≤ 7 days prior to the first dose of investigational product.

Exclusion Criteria:

1. Receiving cancer therapy (chemotherapy or other systemic anti-cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment
2. Prior history of other malignancies.
3. Not recovered to baseline or ≤ grade 1 adverse events from prior anti-cancer treatment.
4. Major surgery within 4 weeks and minor surgery within 2 weeks before the first dose or not fully recovered from surgery; or surgery planned during the time the patient is expected to participate in the study
5. Grade 2 or higher peripheral neuropathy.
6. Active pneumonitis/interstitial lung disease (ILD), a history of pneumonitis/ILD that required systemic steroids, received radiotherapy to lung field within 12 months before the first dose of study intervention, or current clinically relevant-lung disease
7. Symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases, including steroids (>10 mg of prednisone or 4 mg of dexamethasone) and antiepileptic agents.
8. Any other serious ongoing underlying medical conditions, including but not limited to, uncontrolled diabetes mellitus, active uncontrolled infection, vaccination within 4 weeks, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents within 6 months of study entry, gastrointestinal bleeding within 3 months of study entry, severe signs and symptoms of coagulation and clotting disorders.
9. QTc interval ≥450 ms for male or ≥470 ms for female (Fridericia's formula) and patients with congenital long QT syndrome.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: dose escalation; Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles	Drug: BB-1705; BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
Experimental: cohort expansion; BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles	Drug: BB-1705; BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with adverse events and serious adverse events	To evaluate the safety and tolerability of BB-1705	up to 2 years
Number of subjects with dose limiting toxicity (DLT)	Subjects are evaluated for all study drug related and treatment emergent toxicities based on the National Cancer Institute Common Toxicity Criteria for adverse events (NCI-CTCAE)	Cycle 1. Duration of each cycle is 21 days.
MTD	MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle.	Cycle 1. Duration of each cycle is 21 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the serum concentration time curve from time 0 extrapolated to infinity (AUC0-inf)	To characterize the PK of BB-1705	Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.
Maximum observed plasma concentration (Cmax)	To characterize the PK of BB-1705	Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.
Incidence of anti-drug antibodies	To assess the immunogenicity of BB-1705	Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 4, 6, and 8. Duration of each cycle is 21 days.
Objective response	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)
Progression Free Survival	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)
Duration of Response	To assess the preliminary anti-tumor activity of BB-1705	Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years)

Collaborators and Investigators

• Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2022
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: December 29, 2021
• First Submitted That Met QC Criteria: January 19, 2022
• First Posted (Actual): February 1, 2022

Study Record Updates

• Last Update Posted (Estimated): December 20, 2023
• Last Update Submitted That Met QC Criteria: December 14, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: ADC
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: BB-1705-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No